Metronomic Chemotherapy in Breast Cancer as a Strategy to Deliver More Sustainable and Less Toxic Treatments: Time to Debunk the Myth?

Breast cancer is the most commonly diagnosed cancer in women, worldwide. With the increasing burden of breast cancer, the search for more tolerable and sustainable treatments is required, to result in broader access to cancer treatments. Metronomic chemotherapy defines the use of chemotherapy agents based on low-dose, continuous regimens, as opposed to traditional treatments administered for limited intervals, at higher dose.

Blinded independent central review versus local investigator assessment of PFS in RCTs of immunotherapy in advanced cancers: A systematic review and meta-analysis.

Background: Assessment of Progression-free survival (PFS) events by investigators might be inaccurate in randomized controlled trials (RCTs) with open-label design. We explored differences in PFS evaluated by blinded independent central review (BICR) or local investigator assessment (IA) in trials testing immunotherapy (IO) in advanced cancers.

Methods: We systematically reviewed articles of RCTs investigating IO in advanced tumors, published in PubMed-indexed journals up to December 2023.